Sanofi has been granted approval in Europe for a rare blood-clotting disorder treatment using nanobodies.
The European Commission has granted marketing authorization for Cablivi (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi is the first therapeutic specifically indicated for the treatment of aTTP.
The U.S Food & Drug Administration had previously granted the drug a ‘Fast Track’ designation and has an expected target date of Feb. 2019.
Caplacizumab, to be marketed as Cablivi, was developed by Belgium company Ablynx which was acquired by Sanofi earlier this year for $4.53 billion.
Read the full release